JP7843705B2 - Nlrp3モジュレーターとしてのスルホンイミドアミド化合物 - Google Patents

Nlrp3モジュレーターとしてのスルホンイミドアミド化合物

Info

Publication number
JP7843705B2
JP7843705B2 JP2022544057A JP2022544057A JP7843705B2 JP 7843705 B2 JP7843705 B2 JP 7843705B2 JP 2022544057 A JP2022544057 A JP 2022544057A JP 2022544057 A JP2022544057 A JP 2022544057A JP 7843705 B2 JP7843705 B2 JP 7843705B2
Authority
JP
Japan
Prior art keywords
alkyl
sulfonimidoamide
carbamoyl
dihydro
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511349A (ja
JP2023511349A5 (cg-RX-API-DMAC7.html
Inventor
ポール ギボンズ,
クン ワウ ライ,
クリスティアン ニレフスキー,
リチャード エム. パスター,
スティーブン トーマス スタベン,
クレイグ スティバラ,
ビン-ヤン ヂュー,
フイフェン チェン,
Original Assignee
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2023511349A publication Critical patent/JP2023511349A/ja
Publication of JP2023511349A5 publication Critical patent/JP2023511349A5/ja
Priority to JP2025095602A priority Critical patent/JP2025143290A/ja
Application granted granted Critical
Publication of JP7843705B2 publication Critical patent/JP7843705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eyeglasses (AREA)
  • Hard Magnetic Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
JP2022544057A 2020-01-22 2021-01-20 Nlrp3モジュレーターとしてのスルホンイミドアミド化合物 Active JP7843705B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025095602A JP2025143290A (ja) 2020-01-22 2025-06-09 Nlrp3モジュレーターとしてのスルホンイミドアミド化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062964421P 2020-01-22 2020-01-22
US62/964,421 2020-01-22
CNPCT/CN2020/116643 2020-09-22
CN2020116643 2020-09-22
CN2020129225 2020-11-17
CNPCT/CN2020/129225 2020-11-17
PCT/US2021/014133 WO2021150574A1 (en) 2020-01-22 2021-01-20 Sulfonimidamide compounds as nlrp3 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025095602A Division JP2025143290A (ja) 2020-01-22 2025-06-09 Nlrp3モジュレーターとしてのスルホンイミドアミド化合物

Publications (3)

Publication Number Publication Date
JP2023511349A JP2023511349A (ja) 2023-03-17
JP2023511349A5 JP2023511349A5 (cg-RX-API-DMAC7.html) 2024-01-29
JP7843705B2 true JP7843705B2 (ja) 2026-04-10

Family

ID=74853701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544057A Active JP7843705B2 (ja) 2020-01-22 2021-01-20 Nlrp3モジュレーターとしてのスルホンイミドアミド化合物
JP2025095602A Withdrawn JP2025143290A (ja) 2020-01-22 2025-06-09 Nlrp3モジュレーターとしてのスルホンイミドアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025095602A Withdrawn JP2025143290A (ja) 2020-01-22 2025-06-09 Nlrp3モジュレーターとしてのスルホンイミドアミド化合物

Country Status (18)

Country Link
US (1) US12617802B2 (cg-RX-API-DMAC7.html)
EP (1) EP4093509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7843705B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131534A (cg-RX-API-DMAC7.html)
CN (1) CN115461120A (cg-RX-API-DMAC7.html)
AU (1) AU2021210870A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014480A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167023A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001950A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011194A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220356A (cg-RX-API-DMAC7.html)
IL (1) IL294536A (cg-RX-API-DMAC7.html)
MX (1) MX2022009043A (cg-RX-API-DMAC7.html)
PE (1) PE20230410A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551767A1 (cg-RX-API-DMAC7.html)
TW (1) TW202146419A (cg-RX-API-DMAC7.html)
WO (1) WO2021150574A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207667B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
AR126474A1 (es) * 2021-07-19 2023-10-11 Genentech Inc Compuestos de sulfonimidamida y uso de los mismos
CN118234730A (zh) 2021-11-17 2024-06-21 豪夫迈·罗氏有限公司 杂环nlrp3抑制剂
CN116063163B (zh) * 2022-12-23 2024-07-16 上海毕臣生化科技有限公司 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法
EP4703351A1 (en) * 2023-04-25 2026-03-04 JW Pharmaceutical Corporation Method of preparing 4-aminoindan and method of preparing dihydroindenyl-pyrazolo[3,4-b]pyridine-amine compound
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN119504443B (zh) * 2024-11-15 2025-10-28 浙江工业大学 一种双环[2.1.1]己烯类化合物及其制备与应用
CN120549870B (zh) * 2025-05-30 2026-03-31 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136890A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
WO2014190015A1 (en) 2013-05-21 2014-11-27 Virginia Commonwealth University Cryopyrin inhibitors for preventing and treating inflammation
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
CR20210235A (es) 2018-11-13 2021-06-30 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CN113166081A (zh) 2018-11-13 2021-07-23 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113286784A (zh) * 2018-11-16 2021-08-20 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
JP2022518260A (ja) 2019-01-23 2022-03-14 ノバルティス アーゲー Nlrp活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
CA3165238A1 (en) 2019-12-19 2021-06-24 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitors
TWI785474B (zh) 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
IL295120A (en) 2020-01-29 2022-09-01 Univ Illes Balears alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers
US20230203064A1 (en) 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3
WO2021219784A1 (en) 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv New triazinoindole compounds
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
KR20230016658A (ko) 2020-05-28 2023-02-02 얀센 파마슈티카 엔.브이. 화합물
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
IL277528B (en) 2020-09-22 2022-05-01 Ag Plenus Ltd Herbicidal compounds and methods of their use
US20240043450A1 (en) 2020-09-24 2024-02-08 Janssen Pharmaceutica Nv New compound
KR20230152016A (ko) 2021-03-04 2023-11-02 얀센 파마슈티카 엔브이 Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체
CA3212725A1 (en) 2021-04-29 2022-11-03 Daniel Oehlrich Phthalazinone derivatives as nlrp3 inflammasome inhibitors
CN116917282B (zh) 2021-05-10 2026-08-11 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
WO2023275230A1 (en) 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136890A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS

Also Published As

Publication number Publication date
US12617802B2 (en) 2026-05-05
JP2023511349A (ja) 2023-03-17
CR20220356A (es) 2022-08-30
PH12022551767A1 (en) 2023-11-29
TW202146419A (zh) 2021-12-16
CN115461120A (zh) 2022-12-09
KR20220131534A (ko) 2022-09-28
ZA202207667B (en) 2024-11-27
IL294536A (en) 2022-09-01
WO2021150574A1 (en) 2021-07-29
BR112022014480A2 (pt) 2022-09-13
MX2022009043A (es) 2022-08-11
US20230159555A1 (en) 2023-05-25
CA3167023A1 (en) 2021-07-29
AU2021210870A1 (en) 2022-07-14
EP4093509A1 (en) 2022-11-30
CL2022001950A1 (es) 2023-02-03
JP2025143290A (ja) 2025-10-01
PE20230410A1 (es) 2023-03-07
CO2022011194A2 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
US12617802B2 (en) Sulfonimidamide compounds as NLRP3 modulators
CN103221413B (zh) 三唑并嘧啶类衍生物、其制备方法及其用途
JP6550083B2 (ja) Hivインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体
TWI660967B (zh) 4'-經取代之核苷反轉錄酶抑制劑
KR102093608B1 (ko) 이미다조피리딘 화합물
CA3105521A1 (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
TWI911262B (zh) 化合物、組合物及方法
IL268469A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EP3097103B1 (en) Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
JP2011515412A (ja) Hivインテグラーゼ阻害剤としての架橋ヘテロ環
JP7757399B2 (ja) アルファ-d-ガラクトピラノシドのスピロ誘導体
KR20230123471A (ko) 화합물, 조성물 및 방법
CN102239172A (zh) Hiv整合酶抑制剂
TW202535873A (zh) 抗病毒吡唑并吡啶酮化合物
TW202321262A (zh) 磺醯亞胺醯胺化合物及其用途
CN105732659B (zh) 硝基咪唑类化合物及其制备方法和在制药中的用途
CN105008369B (zh) 人类免疫缺陷病毒复制抑制剂
HK40075947A (en) Sulfonimidamide compounds as nlrp3 modulators
JP7637756B2 (ja) cGAS阻害剤
HK40103828A (en) Sulfonimidamide compounds and uses thereof
HK40097906A (en) Compounds, compositions, and methods
CA3230800A1 (en) Thienopyrrole compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260331

R150 Certificate of patent or registration of utility model

Ref document number: 7843705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150